July 22, 2014 6:45 PM ET

Biotechnology

Company Overview of Merck Serono S.A.

Company Overview

Merck Serono S.A., a biopharmaceutical company, discovers, develops, manufactures, and markets prescription medicines of chemical and biological origins. The company develops treatments to manage neurodegenerative diseases, such as multiple sclerosis; oncology therapies to treat colorectal, and head and neck cancer; and a portfolio of fertility drugs for every stage of the reproductive cycle and recombinant versions of various hormones needed to treat infertility. It also provides specialized therapies for patients with selected endocrine and metabolic disorders, such as hyperphenylalaninemia and phenylketonuria, childhood growth hormone and adult growth hormone deficiency, HIV-associated wa...

9, chemin des Mines

Case postale 54

Geneva 20

Geneva,  1211

Switzerland

Founded in 1987

4,775 Employees

Phone:

41 22 414 30 00

Fax:

41 22 414 21 79

Key Executives for Merck Serono S.A.

Chief Executive Officer and President
Age: 54
Head of Global Business Unit Allergy and Chief Executive Officer of Allergopharma
Chief Executive Officer of Consumer Health Division and President of Consumer Health Division
Chief Intellectual Property Counsel
Age: 59
Head of the Global Business Unit Fertility and Metabolic Endocrinology and Member of Executive Management Board
Age: 50
Compensation as of Fiscal Year 2014.

Merck Serono S.A. Key Developments

Merck and Mersana Collaborate to Develop Antibody-Drug Conjugates for Cancer

Merck Serono and Mersana Therapeutics, Inc. have collaborated to develop next-generation antibody-drug conjugates, or ADCs, for cancer. ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site. Mersana and Merck Serono will leverage Mersana's Fleximer technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana's platform technologies and several cytotoxic agents as conjugates. This agreement further underlines Merck Serono's approach to employ a collaborative R&D model, creating strategic partnerships to drive innovation, being consciously agnostic of the source of potential novel assets, and technologies.

Merck Serono Gets FDA Clearance for Auxogyn's Early Embryo Viability Assessment (Eeva) System

Merck Serono announced that the proprietary Early Embryo Viability Assessment (Eeva) System of Merck Seronos strategic partner Auxogyn received clearance from the U.S. Food and Drug Administration (FDA) through its de novo classification process, a regulatory pathway for select novel, low-to-moderate risk medical devices. Merck Serono is the exclusive commercial partner of Auxogyn, for the Eeva System in Europe and Canada.

Merck Serono Announces FDA Clearance for Auxogyn's Early Embryo Viability Assessment (Eeva®) System

Merck Serono announced that the proprietary Early Embryo Viability Assessment (Eeva(R)) System of Merck Seronos strategic partner Auxogyn received clearance from the U.S. Food and Drug Administration (FDA) through its de novo classification process, a regulatory pathway for select novel, low-to-moderate risk medical devices that are first-of-a-kind. Merck Serono is the exclusive commercial partner of Auxogyn Inc., for the Eeva System in Europe and Canada. The Eeva Test, used adjunctively to traditional morphology, is the first and only prognostic, non-invasive embryo test to receive clearance from the FDA. The Eeva Test utilizes proprietary software that automatically analyzes embryo development against scientifically derived cell-division timing parameters captured through continual video imaging. This objective information provided to reproductive endocrinologists and embryologists helps to optimize treatment plans for their patients. The Eeva System received the CE Mark in 2012 and has been commercially available in the European Union ever since, and more recently in Canada since 2013. The potential of the Eeva System led to an expansion of the original partnership agreement to include a licensing agreement between Merck and Auxogyn, announced in April 2014 for the exclusive rights to commercialize the Eeva Test in Europe and Canada. Auxogyn plans to commercialize the Eeva Test in the United States later this year.

Similar Private Companies By Industry

Company Name Region
MykoGreen Biotechnology AG Europe
Numab AG Europe
Proterra, AG Europe
Biogen Idec Switzerland AG Europe
Xigen SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Merck Serono S.A., please visit www.merckserono.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.